RETRACTED ARTICLE: Current prevention and treatment of postoperative nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists: a review

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from